Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
In patients with type 2 diabetes and albuminuria, combining an SGLT2 inhibitor, a GLP-1 receptor agonist, and the nonsteroidal MRA finerenone is projected to add several years of cardiovascular and kidney event-free survival compared with conventional care.
Background
SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone each individually reduce cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combining all three therapies on top of conventional care had not been established.
Study design
Investigators used data from two SGLT2 inhibitor trials (CANVAS and CREDENCE), two ns-MRA trials (FIDELIO-DKD and FIGARO-DKD), and eight GLP-1 receptor agonist trials to estimate the relative effects of combination therapy versus conventional care (renin-angiotensin system blockade and traditional risk factor control). Using actuarial methods, they applied the estimated combination treatment effects to conventional-care participants with type 2 diabetes and urinary albumin-to-creatinine ratio at least 30 mg/g to project absolute and lifetime benefits.
Key findings
Compared with conventional care, combination therapy was associated with a hazard ratio of 0.65 (95% CI, 0.55-0.76) for major adverse cardiovascular events, with an estimated 3-year absolute risk reduction of 4.4% and a number needed to treat of 23. For a 50-year-old patient, projected MACE-free survival was 21.1 years versus 17.9 years with conventional care, a gain of 3.2 years. Additional projected gains included 3.2 years free from hospitalized heart failure, 5.5 years free from chronic kidney disease progression, and 2.4 years of overall survival; attenuated but clinically relevant gains persisted under a conservative assumption of 50% additive effects.
Clinical implications
These projections suggest that early, combined use of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone could yield substantial gains in cardiovascular and kidney event-free and overall survival for patients with type 2 diabetes and albuminuria. The findings support a multi-agent treatment strategy targeting complementary cardiorenal pathways, though the estimates are modeled rather than derived from a single head-to-head trial.
Category
Research
Source
Circulation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.